TIL Stock Overview
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.
Instil Bio Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.33|
|52 Week High||US$23.22|
|52 Week Low||US$3.90|
|1 Month Change||0.57%|
|3 Month Change||-9.66%|
|1 Year Change||-70.60%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-79.84%|
Recent News & Updates
Instil Bio appoints Tim Moore as COO
Instil Bio (NASDAQ:TIL) has appointed Tim Moore to the role of COO. Mr. Moore most recently served as the President and COO of PACT Pharma, a cell therapy company focusing on neo-antigen directed TCR-T cell therapy.
We're Keeping An Eye On Instil Bio's (NASDAQ:TIL) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
|TIL||US Biotechs||US Market|
Return vs Industry: TIL underperformed the US Biotechs industry which returned -19.3% over the past year.
Return vs Market: TIL underperformed the US Market which returned -18.8% over the past year.
|TIL Average Weekly Movement||11.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: TIL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: TIL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.
Instil Bio Fundamentals Summary
|TIL fundamental statistics|
Is TIL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TIL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.63|
|Net Profit Margin||0.00%|
How did TIL perform over the long term?See historical performance and comparison
Is TIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TIL?
Other financial metrics that can be useful for relative valuation.
|What is TIL's n/a Ratio?|
Price to Book Ratio vs Peers
How does TIL's PB Ratio compare to its peers?
|TIL PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
YMAB Y-mAbs Therapeutics
CRBU Caribou Biosciences
TIL Instil Bio
Price-To-Book vs Peers: TIL is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (2.8x).
Price to Earnings Ratio vs Industry
How does TIL's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: TIL is good value based on its Price-To-Book Ratio (1.5x) compared to the US Biotechs industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is TIL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate TIL's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of TIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TIL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TIL's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Instil Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TIL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TIL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TIL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TIL's revenue (95% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: TIL's revenue (95% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TIL is forecast to be unprofitable in 3 years.
Discover growth companies
How has Instil Bio performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TIL is currently unprofitable.
Growing Profit Margin: TIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TIL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: TIL has a negative Return on Equity (-46.14%), as it is currently unprofitable.
Discover strong past performing companies
How is Instil Bio's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TIL's short term assets ($367.7M) exceed its short term liabilities ($43.2M).
Long Term Liabilities: TIL's short term assets ($367.7M) exceed its long term liabilities ($67.0M).
Debt to Equity History and Analysis
Debt Level: TIL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if TIL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TIL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TIL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 69.8% each year.
Discover healthy companies
What is Instil Bio current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Instil Bio Dividend Yield vs Market|
|Company (Instil Bio)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Instil Bio)||n/a|
Notable Dividend: Unable to evaluate TIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TIL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TIL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bronson Crouch (49 yo)
Mr. Bronson Crouch is the Chief Executive Officer and Chairman at Instil Bio, Inc. since November 2018. Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014. Mr....
CEO Compensation Analysis
|Bronson Crouch's Compensation vs Instil Bio Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$36m||US$618k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$6m||US$438k|
Compensation vs Market: Bronson's total compensation ($USD35.78M) is above average for companies of similar size in the US market ($USD3.98M).
Compensation vs Earnings: Bronson's compensation has increased whilst the company is unprofitable.
Experienced Management: TIL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: TIL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Instil Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Instil Bio, Inc.
- Ticker: TIL
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$691.271m
- Shares outstanding: 129.69m
- Website: https://instilbio.com
Number of Employees
- Instil Bio, Inc.
- 3963 Maple Avenue
- Suite 350
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TIL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.